Etirinotecan pegol clinical trials
Also written NKTR-102.
How each study uses etirinotecan pegol is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
10 studies that test it; most in 2008 (4)
| Year | Studies |
|---|---|
| 2008 | 4 |
| 2011 | 2 |
| 2012 | 1 |
| 2013 | 1 |
| 2014 | 1 |
| 2016 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 8 · Other 2
Nektar Therapeutics (8) · Abramson Cancer Center at Penn Medicine (1) · Lawrence Recht (1)
Related medicines
As reviewed, each with the page that says it.
- A conjugate made from Polyethylene Glycols
Studies
Open first, then newest update. How each study uses etirinotecan pegol is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 10
- A Study of Etirinotecan Pegol (NKTR-102) Versus Treatment of Physician's Choice (TPC) in Patients With Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been Previously Treated With an Anthracycline, a Taxane, and CapecitabineCompletedPhase 3Nektar TherapeuticsNCT02915744Written as NKTR-102How we know
- An Extension Study of NKTR-102 in Cancer Patients Previously Enrolled in NKTR-102 StudiesCompletedPhase 2Nektar TherapeuticsNCT01457118Written as NKTR-102 145 mg/m2How we know
- NKTR-102 Versus Irinotecan in Patients With Second-Line, Irinotecan-Naïve, KRAS Mutant, Colorectal CancerCompletedPhase 2Nektar TherapeuticsNCT00856375Written as NKTR-102How we know
- NKTR-102 in Combination With Cetuximab in Patients With Refractory Solid Tumors (Phase 2a) and Metastatic or Locally Advanced Colorectal Cancer (Phase 2b)CompletedPhase 2Nektar TherapeuticsNCT00598975Written as NKTR-102 100 mg/m2How we know
- Study to Evaluate the Safety and Efficacy of NKTR-102 in Patients With Metastatic or Locally Advanced Ovarian CancerCompletedPhase 2Nektar TherapeuticsNCT00806156Written as NKTR-102 q14dHow we know
- The BEACON Study (Breast Cancer Outcomes With NKTR-102)CompletedPhase 3Nektar TherapeuticsNCT01492101Written as NKTR-102How we know
- Etirinotecan Pegol (NKTR-102) in NSCLCCompletedPhase 2Abramson Cancer Center at Penn MedicineNCT01773109Written as Etirinotecan pegol (NKTR-102)How we know
- Study to Evaluate the Safety and Efficacy of NKTR-102 in Patients With Metastatic or Locally Advanced Breast CancerCompletedPhase 2Nektar TherapeuticsNCT00802945Written as NKTR-102How we know
- A Study in Cancer Patients to Evaluate the Effect of a Single Dose of NKTR-102 (Etirinotecan Pegol) on the QTc Interval and to Assess Pharmacokinetics and SafetyCompletedPhase 1Nektar TherapeuticsNCT01976143Written as NKTR-102How we know
- Phase II NKTR-102 In Bevacizumab-Resistant High Grade GliomaCompletedPhase 2Lawrence RechtNCT01663012Written as Etirinotecan pegolHow we know
Codes
What other systems call etirinotecan pegol · ClinicalTrials.gg INT006297
- MeSH (NLM) C581703etirinotecan pegolConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) LJ16641SFTETIRINOTECAN PEGOLConfirmed FDA, NLM
- NCI Thesaurus C74069Etirinotecan PegolOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C581703 | etirinotecan pegol | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | LJ16641SFT | ETIRINOTECAN PEGOL | Confirmed FDA, NLM |
| NCI Thesaurus | C74069 | Etirinotecan Pegol | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.